ERBB2

Chr 17AR

erb-b2 receptor tyrosine kinase 2

Also known as: CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL

The protein is a receptor tyrosine kinase that forms heterodimers with other EGF receptor family members to activate downstream signaling pathways and regulates microtubule stabilization at the cell periphery. Mutations cause autosomal dominant developmental delays, intellectual disability, and growth abnormalities as part of a neurodevelopmental syndrome. The gene is highly constrained against loss-of-function variants (LOEUF 0.397), indicating that haploinsufficiency is likely not tolerated in the general population.

GeneReviewsOMIMResearchSummary from RefSeq, UniProt
MultiplemechanismARLOEUF 0.405 OMIM phenotypes
Clinical SummaryERBB2
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.27) despite low pLI — interpret in context.
📋
ClinVar Variants
6 unique Pathogenic / Likely Pathogenic· 210 VUS of 400 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — ERBB2
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Missense constrained — critical functional residues
LoF Constraint
0.40LOEUF
pLI 0.006
Z-score 5.57
OE 0.27 (0.180.40)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
3.25Z-score
OE missense 0.67 (0.620.72)
510 obs / 762.5 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios
LoF OE0.27 (0.180.40)
00.351.4
Missense OE0.67 (0.620.72)
00.61.4
Synonymous OE0.99
01.21.6
LoF obs/exp: 18 / 67.3Missense obs/exp: 510 / 762.5Syn Z: 0.15
DN
0.7325th %ile
GOF
0.88top 5%
LOF
0.2679th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

400 submitted variants in ClinVar

Classification Summary

Pathogenic6
VUS210
Likely Benign147
Benign5
Conflicting4
6
Pathogenic
210
VUS
147
Likely Benign
5
Benign
4
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
4
2
0
6
Likely Pathogenic
0
0
0
0
0
VUS
13
187
7
3
210
Likely Benign
0
2
66
79
147
Benign
0
0
5
0
5
Conflicting
4
Total131938082372

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ERBB2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Malignant Solid Neoplasm

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

ACTIVE NOT RECRUITING
NCT06136897Phase PHASE2National Cancer Institute (NCI)Started 2017-03-23
Biopsy ProcedureBiospecimen CollectionEchocardiography Test
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableUpper Tract Urothelial Cancer

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

RECRUITING
NCT06820255Phase PHASE4Fondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-01-07
Platinum + GemcitabineAvelumab first-line maintenanceNGS test for DDR alterations
Breast CancerOvarian CancerEndometrial Cancer

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

RECRUITING
NCT07524322Phase PHASE1Regor Pharmaceuticals Inc.Started 2026-04
RGT-490
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Tumor

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

RECRUITING
NCT05982093Phase PHASE2SOLTI Breast Cancer Research GroupStarted 2023-02-03
ElacestrantTriptorelinTamoxifen 20 mg
Neoplasm MetastasisNon-Small Cell Lung Cancer

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

ACTIVE NOT RECRUITING
NCT04886804Phase PHASE1Boehringer IngelheimStarted 2021-07-02
zongertinib
Hormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

NOT YET RECRUITING
NCT06338644Helwan UniversityStarted 2024-07-01
Palbociclib
Breast CancerBreast CarcinomaMalignant Neoplasm of Breast

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

ACTIVE NOT RECRUITING
NCT02204098Phase PHASE1Washington University School of MedicineStarted 2015-01-07
Mammaglobin-A DNA VaccineOptional biopsy
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

ACTIVE NOT RECRUITING
NCT06714617Phase PHASE1SystImmune Inc.Started 2025-04-10
BL-M17D1
NSCLCSCLCHigh Grade Neuroendocrine Cancer

Study of Oral MRT-2359 in Selected Cancer Patients

ACTIVE NOT RECRUITING
NCT05546268Phase PHASE1, PHASE2Monte Rosa Therapeutics, IncStarted 2022-10-12
Oral MRT-2359Oral MRT-2359Oral MRT-2359
Breast CancerTriple Negative Breast CancerCamrelizumab

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

RECRUITING
NCT05475678Phase PHASE2Zhenzhen LiuStarted 2022-12-20
(Carrelizumab + TCb) regimenTCb regimen
HER2-negative Breast Cancer

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

ACTIVE NOT RECRUITING
NCT05889390Phase PHASE2, PHASE3Semmelweis UniversityStarted 2023-02-20
Oncotherm EHY-2030PaclitaxelCarboplatin
Breast Cancer

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

ACTIVE NOT RECRUITING
NCT02955394Phase PHASE2University of Colorado, DenverStarted 2017-09-21
EnzalutamideFulvestrant
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Top 5 results · since 2015Search PubMed ↗